hey @tuts, thanks for your reply, but what im wondering about is the AIPAC results on slide 17.
They show increased cd8 t cell counts in efti group at two later timepoints compared to placebo, but what about at baseline?
This would let us know if the increase in cd8 is due to efti or due to the patient arms just being different at the start of the trial pre-treatment
anyone know why there are no baseline values reported?
Ann: Immutep Corporate Presentation, page-5
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $598.3M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.5¢ | 41.0¢ | $1.132M | 2.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 15565 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 246989 | 7 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |